Answers are grounded in this paper and cite their sources.
Phase II trial investigates decitabine and venetoclax in post-myeloproliferative blast phase, highlighting novel strategies for poor-prognosis secondary acute myeloid leukemia.
The management of patients with acute myeloid leukemia (blast phase) secondary to myeloproliferative neoplasms (MPNs) is extremely challenging and the outcome dismal, with a median overall survival of about 3–6months. Effective therapeutic approaches are lacking, especially when intensive strategies followed by allogeneic transplantation are not feasible. The combination of venetoclax and hypomethylating agents has recently been established as standard for newly diagnosed, unfit patients with de novo acute myeloid leukemia, but the application of this therapeutic modality has not been tested prospectively in the specific context of blast-phase MPNs. ENABLE is an open, phase II clinical trial aimed at verifying the efficacy and safety of the combination of venetoclax and decitabine in patients with post-MPN blast phase.
No takes yet. Share an insight, caveat, or question.
Mannelli et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: